24/7 Market News Snapshot 02 October, 2025 – AngioDynamics, Inc. (NASDAQ:ANGO)

October 2, 2025

DENVER, Colo., 02 October, 2025 (www.247marketnews.com) – (NASDAQ:ANGO) are discussed in this article.
AngioDynamics, Inc. (ANGO), a leading medical technology company specializing in vascular health and cancer treatment solutions, has seen notable fluctuations in its stock performance today, with shares opening at $12.73 and currently trading at $12.13, marking a decline of approximately 9.58%. This shift follows the previous closing price of $11.07, reflecting heightened volatility in trading, evidenced by over 1.32 million shares exchanged. Such activity may indicate increased investor engagement, potentially linked to recent developments or market dynamics. Analysts are advised to keep an eye on support levels around $11.07 and resistance near the opening price of $12.73 to gauge possible rebound or further declines.

Concurrently, AngioDynamics has announced strong financial results for the first quarter of fiscal year 2026, which ended on August 31, 2025. The company reported net sales of $75.7 million for this quarter, representing a year-over-year growth of 12.2%. Particularly impressive was the company’s Med Tech segment, which achieved net sales of $35.3 million, marking a 26.1% increase, driven by significant contributions from innovative technologies such as the Auryon peripheral atherectomy platform and the AlphaVac Mechanical Thrombectomy system.

Additionally, the company reached several key clinical milestones, including the start of pivotal trials for new treatment technologies aimed at critical limb ischemia and pulmonary embolism. Results from the NanoKnife PRESERVE study were also published in a prestigious urological journal, highlighting the technology’s effectiveness in prostate cancer treatment.

President and CEO Jim Clemmer emphasized the company’s dedication to operational excellence and innovation. AngioDynamics projects an increase in net sales for fiscal year 2026, estimating between $308 and $313 million, and anticipates generating positive cash flow throughout the year, positioning itself for continued growth and a meaningful impact in the healthcare sector.

Related news for (ANGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.